NCT05486195View on ClinicalTrials.gov

A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 14, 2019

Primary Completion Date

July 29, 2019

Study Completion Date

March 11, 2020

Conditions
Cognitive Disorders
Interventions
DRUG

SDI-118

SDI-118 Powder in Capsule

DRUG

Placebo

Matching Placebo

Trial Locations (1)

B-3000

Centre for Clinical Pharmacology, UZ Leuven, Leuven

Sponsors

Lead Sponsor

AbbVie

Collaborators (1)

Syndesi Therapeutics
All Listed Sponsors
collaborator

Syndesi Therapeutics

INDUSTRY

collaborator

KU Leuven

OTHER

lead

AbbVie

INDUSTRY